表紙
市場調查報告書

生物相似藥的全球市場 - 產業洞察,趨勢,預測,市場機會分析 2017年∼2025年

Biosimilars Market - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2017-2025

出版商 Coherent Market Insights 商品編碼 833116
出版日期 內容資訊 英文 231 Pages
商品交期: 2-3個工作天內
價格
Back to Top
生物相似藥的全球市場 - 產業洞察,趨勢,預測,市場機會分析 2017年∼2025年 Biosimilars Market - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2017-2025
出版日期: 2019年04月16日內容資訊: 英文 231 Pages
簡介

生物相似藥是含有有效成分的生物醫藥品。首發醫藥品的專利屆滿的情況下製造,與首發醫藥品具同等性。使用於癌症和腫瘤,及氣喘和關節炎等非感染性疾病的治療。

本報告提供全球生物相似藥市場調查,市場概要,各醫藥品分類、治療領域、通路、地區的市場規模的變化與預測,市場成長要素及阻礙因素分析,市場機會,開發平台分析,競爭情形,主要企業的簡介等全面性資訊。

目錄

第1章 調查目的與前提條件

  • 調查目的
  • 前提條件
  • 簡稱

第2章 市場概要

  • 報告概要
    • 市場定義和範圍
  • 摘要整理
    • 市場片段:各醫藥品分類
    • 市場片段:各治療領域
    • 市場片段:各銷售管道
    • 市場片段:各地區
  • Coherent Opportunity Map(COM)

第3章 市場動態,法規,趨勢分析

  • 市場動態
    • 成長要素
    • 阻礙因素
    • 市場機會
  • 影響分析
  • 市場趨勢
  • 主要的開發
  • 開發平台分析
  • 供應鏈分析
  • 生物相似藥的成本效益
  • 償付方案
  • 法規情形
  • 流行病學分析
  • PEST分析
  • 波特的五力分析

第4章 全球生物相似藥市場:各醫藥品分類

  • 簡介
  • 重組的人體生長荷爾蒙(rhGH)
  • 顆粒細胞增生因子(Filgrastim)
  • 胰島素
  • 抗凝固藥
  • 融合蛋白質
  • 促血紅細胞生長素(EPO)
  • 單株抗體
  • 促濾泡素
  • 其他

第5章 全球生物相似藥市場:各治療領域

  • 簡介
  • 癌症、腫瘤
  • 免疫
  • 血液
  • 荷爾蒙療法
  • 代謝異常
  • 其他

第6章 全球生物相似藥市場:各銷售管道

  • 簡介
  • 醫院藥局
  • 零售藥局
  • 專門藥局

第7章 全球生物相似藥市場:各地區

  • 簡介
  • 北美
  • 歐洲
  • 亞太地區
  • 中南美
  • 非洲
  • 中東

第8章 競爭環境

  • 企業簡介
    • Novartis AG
    • Pfizer, Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Celltrion Healthcare Co., Ltd.
    • Biocon Limited
    • Amgen, Inc.
    • Dr. Reddy's Laboratories
    • Sanofi S.A.
  • 分析師的意見

第9章 Section

  • 參考文獻
  • 調查方法
  • 關於Coherent Market Insights
目錄

Biosimilars are biopharmaceutical drugs that have active components and are similar to the drugs, which have been previously licensed. They are identical copies of the original product and can be manufactured only when the patent for the original innovator product expires. Biosimilars are majorly used in therapeutic applications for the treatment of various types of cancer and non-communicable diseases (asthma and arthritis).

Increasing prevalence of cancer is expected to boost growth of the biosimilars market. For instance, according to National Institute of Cancer Prevention and Research (NICPR), in 2018, 1,62,468 new cases and 87,090 deaths were reported due to breast cancer in India. Biosimilars are designed to be highly similar to originator biologic products, which represents an opportunity to increase access and reduce costs for patients and healthcare systems.

Market Dynamics

Increasing number of biosimilar approvals in clinical management of various diseases such as diabetes and hormonal imbalance is expected to drive growth of the biosimilars market. According to the Generics and Biosimilars Initiative (GABI) 2017 report, around 40 different biosimilars were approved in Europe, covering several different therapeutic classes: granulocyte colony-stimulating factors, and erythropoiesis-stimulating agents (ESAs), among others.

Moreover, increasing research and development in biosimilars, robust biosimilar pipeline portfolio, and support from healthcare regulatory bodies in fast lining biosimilar approvals are some of the major factors that are expected to drive growth of the market. The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) both provide guidance for the development of biosimilar drugs. However, stringent regulatory guidelines for development and manufacturing of biosimilars and fragile process of biosimilars production are expected to negatively impact growth of the global biosimilars market.

Key features of the study:

  • This report provides in-depth analysis of the biosimilars market, market size (US$ Mn), and Compound Annual Growth Rate (CAGR (%)) for the forecast period: 2018 - 2026, considering 2017, as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global biosimilars market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
  • Key players covered as a part of this study include Novartis AG, Pfizer, Inc., Teva Pharmaceutical Industries Ltd., Celltrion Healthcare Co., Ltd., Biocon Limited, Amgen, Inc., Dr. Reddy's Laboratories, and Sanofi S.A.
  • Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, government initiatives, technological up-gradation, market expansion, and marketing tactics
  • The global biosimilars market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for biosimilars market, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation:

  • Global Biosimilars Market, By Drug Class:
    • Recombinant Human Growth Hormone
    • Granulocyte Colony-Stimulating Factor
    • Insulin
    • Anticoagulants
    • Fusion Proteins
    • Erythropoietin
    • Monoclonal Antibodies
    • Follitropin
    • Others
  • Global Biosimilars Market, By Therapy Type:
    • Oncology
    • Immunology
    • Hematology
    • Hormone Therapy
    • Metabolic Disorders
    • Others
  • Global Biosimilars Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Specialty Pharmacies
  • Global Biosimilars Market, By Region:
    • North America
      • By Country:
    • U.S.
    • Canada
      • By Drug Class:
    • Recombinant Human Growth Hormone
    • Granulocyte Colony-Stimulating Factor
    • Insulin
    • Anticoagulants
    • Fusion Proteins
    • Erythropoietin
    • Monoclonal Antibodies
    • Follitropin
    • Others
      • By Therapy Type:
    • Oncology
    • Immunology
    • Hematology
    • Hormone Therapy
    • Metabolic Disorders
    • Others
      • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Specialty Pharmacies
    • Europe
      • By Country:
    • U.K.
    • Germany
    • Italy
    • Spain
    • France
    • Russia
    • Rest of Europe
      • By Drug Class:
    • Recombinant Human Growth Hormone
    • Granulocyte Colony-Stimulating Factor
    • Insulin
    • Anticoagulants
    • Fusion Proteins
    • Erythropoietin
    • Monoclonal Antibodies
    • Follitropin
    • Others
      • By Therapy Type:
    • Oncology
    • Immunology
    • Hematology
    • Hormone Therapy
    • Metabolic Disorders
    • Others
      • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Specialty Pharmacies
    • Asia Pacific
      • By Country:
    • Australia
    • India
    • China
    • Japan
    • ASEAN
    • South Korea
    • Rest of Asia Pacific
      • By Drug Class:
    • Recombinant Human Growth Hormone
    • Granulocyte Colony-Stimulating Factor
    • Insulin
    • Anticoagulants
    • Fusion Proteins
    • Erythropoietin
    • Monoclonal Antibodies
    • Follitropin
    • Others
      • By Therapy Type:
    • Oncology
    • Immunology
    • Hematology
    • Hormone Therapy
    • Metabolic Disorders
    • Others
      • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Specialty Pharmacies
    • Latin America
      • By Country:
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
      • By Drug Class:
    • Recombinant Human Growth Hormone
    • Granulocyte Colony-Stimulating Factor
    • Insulin
    • Anticoagulants
    • Fusion Proteins
    • Erythropoietin
    • Monoclonal Antibodies
    • Follitropin
    • Others
      • By Therapy Type:
    • Oncology
    • Immunology
    • Hematology
    • Hormone Therapy
    • Metabolic Disorders
    • Others
      • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Specialty Pharmacies
    • Middle East
      • By Country:
    • GCC
    • Israel
    • Rest of Middle East
      • By Drug Class:
    • Recombinant Human Growth Hormone
    • Granulocyte Colony-Stimulating Factor
    • Insulin
    • Anticoagulants
    • Fusion Proteins
    • Erythropoietin
    • Monoclonal Antibodies
    • Follitropin
    • Others
      • By Therapy Type:
    • Oncology
    • Immunology
    • Hematology
    • Hormone Therapy
    • Metabolic Disorders
    • Others
      • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Specialty Pharmacies
    • Africa
      • By Country:
    • South Africa
    • Central Africa
    • North Africa
      • By Drug Class:
    • Recombinant Human Growth Hormone
    • Granulocyte Colony-Stimulating Factor
    • Insulin
    • Anticoagulants
    • Fusion Proteins
    • Erythropoietin
    • Monoclonal Antibodies
    • Follitropin
    • Others
      • By Therapy Type:
    • Oncology
    • Immunology
    • Hematology
    • Hormone Therapy
    • Metabolic Disorders
    • Others
      • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Specialty Pharmacies
  • Company Profiles
    • Novartis AG *
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • Pfizer, Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Celltrion Healthcare Co., Ltd.
    • Biocon Limited
    • Amgen, Inc.
    • Dr. Reddy's Laboratories
    • Sanofi S.A.

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objective and Assumption

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Overview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Drug Class
    • Market Snippet, By Therapy Type
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Market Trends
  • Key Developments
  • Pipeline Analysis
  • Supply Chain Analysis
  • Cost Effectiveness of Biosimilars
  • Reimbursement Scenario
  • Regulatory Landscape
  • Epidemiology Analysis
  • PEST Analysis
  • Porter's Five Forces model

4. Global Biosimilars Market, By Drug Class, 2018 - 2026, (US$ Million)

  • Introduction
    • Market Share Analysis, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, 2017 - 2026
    • Segment Trends
  • Recombinant Human Growth Hormone (rhGH)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
  • Granulocyte Colony-Stimulating Factor (Filgrastim)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
  • Insulin
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
  • Anticoagulants
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
  • Fusion Proteins
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
  • Erythropoietin (EPO)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
  • Monoclonal Antibodies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
  • Follitropin
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)

5. Global Biosimilars Market, By Therapy Type, 2018 - 2026, (US$ Million)

  • Introduction
    • Market Share Analysis, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, 2017 - 2026
    • Segment Trends
  • Oncology
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
  • Immunology
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
  • Hematology
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
  • Hormone Therapy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
  • Metabolic Disorders
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)

6. Global Biosimilars Market, By Distribution Channel, 2018 - 2026, (US$ Million)

  • Introduction
    • Market Share Analysis, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, 2017 - 2026
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
  • Specialty Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)

7. Global Biosimilars Market, By Region, 2018 - 2026, (US$ Million)

  • Introduction
    • Market Share Analysis, By Region, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, By Region, 2017 - 2026
    • Regional Trends
  • North America
    • Market Size and Forecast, By Drug Class, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By Therapy Type, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By Country, 2018 - 2026, (US$ Million)
    • U.S.
    • Canada
  • Europe
    • Market Size and Forecast, By Drug Class, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By Therapy Type, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By Country, 2018 - 2026, (US$ Million)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Market Size and Forecast, By Drug Class, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By Therapy Type, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By Country, 2018 - 2026, (US$ Million)
    • China
    • Japan
    • India
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Market Size and Forecast, By Drug Class, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By Therapy Type, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By Country, 2018 - 2026, (US$ Million)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Africa
    • Market Size and Forecast, By Drug Class, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By Therapy Type, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By Country, 2018 - 2026, (US$ Million)
    • North Africa
    • Central Africa
    • South Africa
  • Middle East
    • Market Size and Forecast, By Drug Class, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By Therapy Type, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By Country, 2018 - 2026, (US$ Million)
    • GCC Countries
    • Israel
    • Rest of Middle East

8. Competitive Landscape

  • Company Profiles
    • Novartis AG
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Pfizer, Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Teva Pharmaceutical Industries Ltd.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Celltrion Healthcare Co., Ltd.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Biocon Limited
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Amgen, Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Dr. Reddy's Laboratories
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Sanofi S.A.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
  • Analyst Views

9. Section

  • References
  • Research Methodology
  • About Us and Sales Contact
Back to Top